Clinical Trial

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Study acronym: RAISE
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Protocol Amendment History 1 change
minor Trial arms changed: 2 -> 1 2026-06-12
Trial Details
NCT Number NCT06409832
Lead Sponsor University of Florence
Collaborators: IRCCS National Neurological Institute "C. Mondino" Foundation, Società Italiana per lo Studio delle Cefalee, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Università degli Studi dell'Aquila, University of Roma La Sapienza, Azienda Ospedaliero Universitaria Policlinico Modena, Ospedale di Piove di Sacco, Azienda Ospedaliero-Universitaria di Parma, Azienda Ospedaliera S. Maria della Misericordia, A.O.U. Città della Salute e della Scienza, Cliniche Humanitas Gavazzeni, University of Campania Luigi Vanvitelli, Ospedale Santo Stefano, Azienda Policlinico Umberto I, Auxologico San Luca, Asst Degli Spedali Civili Di Brescia, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Conditions Migraine, Migraine With Aura, Migraine Without Aura
Enrollment 100 participants
Start Date 2024-03-26
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-11